NCT05062239

Brief Summary

Statins have rapid and significant actions that have potentially important (but not yet proven) implications for postoperative atrial fibrillation and cardiac protection in patients undergoing cardiac surgery. The focus of this study is, therefore, on patients having surgical aortic valve replacement (with aortotomy) and the development of postoperative atrial fibrillation (POAF). Our aims are: to investigate the risk of POAF, infection or other complications after SAVR in continuous versus preoperative discontinuous treatment with statins. The study is a single centre randomized controlled trial with continuance treatment with statin vs. discontinuance (7 to 14 days prior surgery until the 30th post-operative day included), on patients undergoing elective solitary SAVR with bioprosthesis with prior usage of statins the last 3 months and of at least 7 days. This randomized studies will address 2 separate hypotheses in patients undergoing open heart operation with solitary aortic valve replacement with a bioprosthetic valve that

  1. 1.Discontinuation of HMG-CoA reductase inhibitors 7 to 14 days preoperative until 30 days postoperative of AVR in patients with prior use of HMG-CoA reductase inhibitors is not associated with increased early (\<30 days) risk of POAF.
  2. 2.Discontinuation of HMG-CoA reductase inhibitors 7 to 14 days preoperative until 30 days postoperative of AVR in patients with prior use of HMG-CoA reductase inhibitors is not associated with increased early (\<30 days) and intermediate (\<1 year) risk of mortality, MI, stroke and rehospitalisation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
9mo left

Started Apr 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress85%
Apr 2022Feb 2027

First Submitted

Initial submission to the registry

August 19, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

September 30, 2021

Completed
6 months until next milestone

Study Start

First participant enrolled

April 1, 2022

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Last Updated

April 23, 2025

Status Verified

April 1, 2025

Enrollment Period

4.8 years

First QC Date

August 19, 2021

Last Update Submit

April 22, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • Number of Participants with POAF - In-hospital

    In-hospital POAF assessed by Holter monitoring.

    In-hospital up to 10 days.

  • Number of Participants with POAF - Early

    Early assessed by anamnesis and electronic health record (EHR).

    Early (≤30 days) incidence of POAF

  • Duration of POAF in-hospital

    Duration of POAF monitered with continuous ECG monitoring (eight-- lead ward monitor) up to 24 weeks.

    In-hospital

Secondary Outcomes (22)

  • Number of Participants with NOAF

    Intermediate (1 year) incidence of NOAF

  • Rate of all-cause mortality - In-hospital

    In-hospital up to 10 days.

  • Rate of all-cause mortality - Early

    Early (≤30 days)

  • Rate of all-cause mortality - intermediate

    Intermediate (1 year)

  • Myocardial injury - Tn

    After surgery until discharge up to 10 days

  • +17 more secondary outcomes

Study Arms (2)

Continuance

ACTIVE COMPARATOR

Continuance prior statin therapy.

Drug: No-intervention.

Discontinuance

EXPERIMENTAL

Discontinuance prior statin therapy. Duration: From 7 to 14 days prior to surgery until 30 days postoperative

Drug: Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative

Interventions

Continuance of prior statin therapy

Continuance

Eligibility Criteria

Age60 Years - 95 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing elective solitary SAVR with bioprosthesis
  • Patients who are in sinus rhythm and not taking any anti-arrhythmic medication, other than beta-adrenergic blocking agents, at the time of surgery
  • In treatment with HMG-CoA reductase inhibitors in the past 3 months and of at least 7 days
  • Age \>60 years
  • Willingness and provision of informed consent to be randomized

You may not qualify if:

  • Prior history of atrial fibrillation
  • Prior history of cardiac surgery
  • Hepatic dysfunction (Alanin-aminotransferase more than twice the upper limit)
  • Creatinine \>200 µmol/L

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Odense University Hospital

Odense, 5000, Denmark

RECRUITING

Related Publications (47)

  • LaPar DJ, Crosby IK, Rich JB, Fonner E Jr, Kron IL, Ailawadi G, Speir AM; Investigators for Virginia Cardiac Surgery Quality Initiative. A contemporary cost analysis of postoperative morbidity after coronary artery bypass grafting with and without concomitant aortic valve replacement to improve patient quality and cost-effective care. Ann Thorac Surg. 2013 Nov;96(5):1621-7. doi: 10.1016/j.athoracsur.2013.05.050. Epub 2013 Aug 21.

    PMID: 23972932BACKGROUND
  • Brown JM, O'Brien SM, Wu C, Sikora JA, Griffith BP, Gammie JS. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J Thorac Cardiovasc Surg. 2009 Jan;137(1):82-90. doi: 10.1016/j.jtcvs.2008.08.015.

    PMID: 19154908BACKGROUND
  • Maesen B, Nijs J, Maessen J, Allessie M, Schotten U. Post-operative atrial fibrillation: a maze of mechanisms. Europace. 2012 Feb;14(2):159-74. doi: 10.1093/europace/eur208. Epub 2011 Aug 6.

    PMID: 21821851BACKGROUND
  • Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. No abstract available.

    PMID: 32860505BACKGROUND
  • Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, Whitlock RP. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD003611. doi: 10.1002/14651858.CD003611.pub3.

    PMID: 23440790BACKGROUND
  • AlTurki A, Marafi M, Proietti R, Cardinale D, Blackwell R, Dorian P, Bessissow A, Vieira L, Greiss I, Essebag V, Healey JS, Huynh T. Major Adverse Cardiovascular Events Associated With Postoperative Atrial Fibrillation After Noncardiac Surgery: A Systematic Review and Meta-Analysis. Circ Arrhythm Electrophysiol. 2020 Jan;13(1):e007437. doi: 10.1161/CIRCEP.119.007437. Epub 2020 Jan 16.

    PMID: 31944855BACKGROUND
  • Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial fibrillation: mechanisms, manifestations and management. Nat Rev Cardiol. 2019 Jul;16(7):417-436. doi: 10.1038/s41569-019-0166-5.

    PMID: 30792496BACKGROUND
  • Greenberg JW, Lancaster TS, Schuessler RB, Melby SJ. Postoperative atrial fibrillation following cardiac surgery: a persistent complication. Eur J Cardiothorac Surg. 2017 Oct 1;52(4):665-672. doi: 10.1093/ejcts/ezx039.

    PMID: 28369234BACKGROUND
  • Aguilar M, Dobrev D, Nattel S. Postoperative Atrial Fibrillation: Features, Mechanisms, and Clinical Management. Card Electrophysiol Clin. 2021 Mar;13(1):123-132. doi: 10.1016/j.ccep.2020.11.010.

    PMID: 33516390BACKGROUND
  • Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008 Jan 1;51(1):68-74. doi: 10.1016/j.jacc.2007.07.085.

    PMID: 18174039BACKGROUND
  • Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonopoulos A, Marinou K, Nahar K, Jayaram R, Tousoulis D, Bakogiannis C, Sayeed R, Triantafyllou C, Koumallos N, Psarros C, Miliou A, Stefanadis C, Channon KM, Casadei B. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll Cardiol. 2012 Jan 3;59(1):60-70. doi: 10.1016/j.jacc.2011.08.062.

    PMID: 22192670BACKGROUND
  • Scott L Jr, Li N, Dobrev D. Role of inflammatory signaling in atrial fibrillation. Int J Cardiol. 2019 Jul 15;287:195-200. doi: 10.1016/j.ijcard.2018.10.020. Epub 2018 Oct 4.

    PMID: 30316645BACKGROUND
  • Wong CX, Ganesan AN, Selvanayagam JB. Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J. 2017 May 1;38(17):1294-1302. doi: 10.1093/eurheartj/ehw045.

    PMID: 26935271BACKGROUND
  • Halonen J, Halonen P, Jarvinen O, Taskinen P, Auvinen T, Tarkka M, Hippelainen M, Juvonen T, Hartikainen J, Hakala T. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA. 2007 Apr 11;297(14):1562-7. doi: 10.1001/jama.297.14.1562.

    PMID: 17426275BACKGROUND
  • Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, Collins R, Casadei B. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med. 2016 May 5;374(18):1744-53. doi: 10.1056/NEJMoa1507750.

    PMID: 27144849BACKGROUND
  • Pinho-Gomes AC, Reilly S, Brandes RP, Casadei B. Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins. Antioxid Redox Signal. 2014 Mar 10;20(8):1268-85. doi: 10.1089/ars.2013.5542. Epub 2013 Oct 19.

    PMID: 23924190BACKGROUND
  • Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017 Jan 6;120(1):229-243. doi: 10.1161/CIRCRESAHA.116.308537.

    PMID: 28057795BACKGROUND
  • Thiago L, Tsuji SR, Nyong J, Puga ME, Gois AF, Macedo CR, Valente O, Atallah AN. Statins for aortic valve stenosis. Cochrane Database Syst Rev. 2016 Sep 5;9(9):CD009571. doi: 10.1002/14651858.CD009571.pub2.

    PMID: 27594276BACKGROUND
  • Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004 Jun 15;109(23 Suppl 1):III39-43. doi: 10.1161/01.CIR.0000131517.20177.5a.

    PMID: 15198965BACKGROUND
  • Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003 Jan;63(1):12-23. doi: 10.1046/j.1523-1755.2003.00744.x.

    PMID: 12472764BACKGROUND
  • Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol. 2013 Jan;28(1):7-18. doi: 10.1097/HCO.0b013e32835b0956.

    PMID: 23160338BACKGROUND
  • Fang WT, Li HJ, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2012 Nov;74(5):744-56. doi: 10.1111/j.1365-2125.2012.04258.x.

    PMID: 22376147BACKGROUND
  • Mannacio VA, Iorio D, De Amicis V, Di Lello F, Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg. 2008 Dec;136(6):1541-8. doi: 10.1016/j.jtcvs.2008.06.038. Epub 2008 Aug 15.

    PMID: 19114204BACKGROUND
  • Almansob MA, Xu B, Zhou L, Hu XX, Chen W, Chang FJ, Ci HB, Yao JP, Xu YQ, Yao FJ, Liu DH, Zhang WB, Tang BY, Wang ZP, Ou JS. Simvastatin reduces myocardial injury undergoing noncoronary artery cardiac surgery: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2304-13. doi: 10.1161/ATVBAHA.112.252098. Epub 2012 Jul 12.

    PMID: 22796581BACKGROUND
  • Kuhn EW, Liakopoulos OJ, Stange S, Deppe AC, Slottosch I, Choi YH, Wahlers T. Preoperative statin therapy in cardiac surgery: a meta-analysis of 90,000 patients. Eur J Cardiothorac Surg. 2014 Jan;45(1):17-26; discussion 26. doi: 10.1093/ejcts/ezt181. Epub 2013 Apr 5.

    PMID: 23562936BACKGROUND
  • Kuhn EW, Slottosch I, Wahlers T, Liakopoulos OJ. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev. 2015 Aug 13;(8):CD008493. doi: 10.1002/14651858.CD008493.pub3.

    PMID: 26270008BACKGROUND
  • Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006 Oct 3;114(14):1455-61. doi: 10.1161/CIRCULATIONAHA.106.621763. Epub 2006 Sep 25.

    PMID: 17000910BACKGROUND
  • Ji Q, Mei Y, Wang X, Sun Y, Feng J, Cai J, Xie S, Chi L. Effect of preoperative atorvastatin therapy on atrial fibrillation following off-pump coronary artery bypass grafting. Circ J. 2009 Dec;73(12):2244-9. doi: 10.1253/circj.cj-09-0352. Epub 2009 Oct 13.

    PMID: 19822977BACKGROUND
  • Sun Y, Ji Q, Mei Y, Wang X, Feng J, Cai J, Chi L. Role of preoperative atorvastatin administration in protection against postoperative atrial fibrillation following conventional coronary artery bypass grafting. Int Heart J. 2011;52(1):7-11. doi: 10.1536/ihj.52.7.

    PMID: 21321461BACKGROUND
  • Zhang L, Zhang S, Jiang H, Sun A, Wang Y, Zou Y, Ge J, Chen H. Effects of statin therapy on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials. Arch Med Res. 2010 Aug;41(6):464-71. doi: 10.1016/j.arcmed.2010.08.009.

    PMID: 21044751BACKGROUND
  • Vukovic PM, Maravic-Stojkovic VR, Peric MS, Jovic MDj, Cirkovic MV, Gradinac SDj, Djukanovic BP, Milojevic PS. Steroids and statins: an old and a new anti-inflammatory strategy compared. Perfusion. 2011 Jan;26(1):31-7. doi: 10.1177/0267659110385607. Epub 2010 Oct 4.

    PMID: 20921085BACKGROUND
  • Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, Antonopoulos AS, Demosthenous M, Miliou A, Psarros C, Marinou K, Sfyras N, Economopoulos G, Casadei B, Channon KM, Stefanadis C. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation. 2010 Sep 14;122(11 Suppl):S66-73. doi: 10.1161/CIRCULATIONAHA.109.927376.

    PMID: 20837928BACKGROUND
  • Song YB, On YK, Kim JH, Shin DH, Kim JS, Sung J, Lee SH, Kim WS, Lee YT. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J. 2008 Aug;156(2):373.e9-16. doi: 10.1016/j.ahj.2008.04.020. Epub 2008 Jun 17.

    PMID: 18657672BACKGROUND
  • Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agro F, Carassiti M, Covino E. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med. 2006 Mar;34(3):660-7. doi: 10.1097/01.CCM.0000201407.89977.EA.

    PMID: 16505650BACKGROUND
  • Macin SM, Perna ER, Farias EF, Franciosi V, Cialzeta JR, Brizuela M, Medina F, Tajer C, Doval H, Badaracco R. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J. 2005 Mar;149(3):451-7. doi: 10.1016/j.ahj.2004.07.041.

    PMID: 15864233BACKGROUND
  • Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 6;352(1):20-8. doi: 10.1056/NEJMoa042378.

    PMID: 15635109BACKGROUND
  • Hashemzadeh K, Dehdilani M, Dehdilani M. Postoperative Atrial Fibrillation following Open Cardiac Surgery: Predisposing Factors and Complications. J Cardiovasc Thorac Res. 2013;5(3):101-7. doi: 10.5681/jcvtr.2013.022. Epub 2013 Oct 5.

    PMID: 24252985BACKGROUND
  • Fragao-Marques M, Mancio J, Oliveira J, Falcao-Pires I, Leite-Moreira A. Gender Differences in Predictors and Long-Term Mortality of New-Onset Postoperative Atrial Fibrillation Following Isolated Aortic Valve Replacement Surgery. Ann Thorac Cardiovasc Surg. 2020 Dec 20;26(6):342-351. doi: 10.5761/atcs.oa.19-00314. Epub 2020 Apr 28.

    PMID: 32350163BACKGROUND
  • Turagam MK, Downey FX, Kress DC, Sra J, Tajik AJ, Jahangir A. Pharmacological strategies for prevention of postoperative atrial fibrillation. Expert Rev Clin Pharmacol. 2015 Mar;8(2):233-50. doi: 10.1586/17512433.2015.1018182.

    PMID: 25697411BACKGROUND
  • Zebis LR, Christensen TD, Thomsen HF, Mikkelsen MM, Folkersen L, Sorensen HT, Hjortdal VE. Practical regimen for amiodarone use in preventing postoperative atrial fibrillation. Ann Thorac Surg. 2007 Apr;83(4):1326-31. doi: 10.1016/j.athoracsur.2006.09.096.

    PMID: 17383335BACKGROUND
  • Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation. 2002 Jul 2;106(1):75-80. doi: 10.1161/01.cir.0000021113.44111.3e.

    PMID: 12093773BACKGROUND
  • Taira CA, Opezzo JA, Mayer MA, Hocht C. Cardiovascular drugs inducing QT prolongation: facts and evidence. Curr Drug Saf. 2010 Jan;5(1):65-72. doi: 10.2174/157488610789869229.

    PMID: 20210721BACKGROUND
  • Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004816. doi: 10.1002/14651858.CD004816.pub5.

    PMID: 23440795BACKGROUND
  • Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015 Mar 12;2015(3):CD008226. doi: 10.1002/14651858.CD008226.pub3.

    PMID: 25760954BACKGROUND
  • Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006 Jan 1;97(1):61-7. doi: 10.1016/j.amjcard.2005.07.108. Epub 2005 Nov 15.

    PMID: 16377285BACKGROUND
  • Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.

    PMID: 21067804BACKGROUND
  • Hansen MR, Hrobjartsson A, Pottegard A, Damkier P, Madsen KG, Pareek M, Olesen M, Hallas J. Postponement of cardiovascular outcomes by statin use: A systematic review and meta-analysis of randomized clinical trials. Basic Clin Pharmacol Toxicol. 2021 Feb;128(2):286-296. doi: 10.1111/bcpt.13485. Epub 2020 Oct 8.

    PMID: 32896109BACKGROUND

MeSH Terms

Interventions

Postoperative Period

Intervention Hierarchy (Ancestors)

Perioperative PeriodSurgical Procedures, OperativePatient CareHealth ServicesHealth Care Facilities Workforce and Services

Central Study Contacts

Lytfi Krasniqi, MD

CONTACT

Lars Riber, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Discontinuous of statin Intervention: Discontinuous of statin, n = 50 Length of preoperative discontinuous: 7 to 14 days prior to surgery Length of postoperative discontinuous: 30 days Control group: continuing medication, n = 50 No withdrawal study could be found in the literature. We therefore estimate that 100 patients with 50 patients in each group will be enough to observe significant differences, if withdrawal statin should be a clinically manifested issue for the risk of POAF from 36% to 66%. Sample size Continuance of statins: 50 Discontinuance of statins: 50
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
MD, Associate Professor, Ph.D., DMSc

Study Record Dates

First Submitted

August 19, 2021

First Posted

September 30, 2021

Study Start

April 1, 2022

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2027

Last Updated

April 23, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will share

Data will be available in anonymized form in accordance with GDPR upon reasonable request. Rules for external researchers to apply for and access data will be laid out towards the end of the study.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
TBA
Access Criteria
TBA

Locations